Saturday, 21 December 2024
  
Login

Australia's most trusted
source of pharma news

Saturday, 21 December 2024
News

Novo's $25b deal to boost supply

Posted 7 February 2024 AM

Novo Nordisk has moved to shore up its supply of Ozempic and Wegovy in the face of overwhelming global demand by taking control of three fill-finish sites.

The acquisition is part of a deal by parent company Novo Holdings to buy CDMO Catalent for $25.4 billion (US$16.5 billion). Novo Nordisk will pay $16.9 billion (US$11 billion) to take control of three manufacturing sites specialised in sterile filling of drugs.

To see the whole article, please login

Popular

Who got booted to the May meet?
Best company Christmas gift is...
First out the door in '25?
He's back: Ex-GM wins CEO role
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home